BMS's Early Oncology Head On Novel IO Approaches & Disruptions
Executive Summary
BMS's early oncology chief Tim Reilly says the company's sprawling immuno-oncology pipeline might look "haphazard," but there is beauty in the bedlam.
You may also be interested in...
Roche Pushes The Boundaries Of Cancer Immunotherapy
Roche is betting that its tumor immunophenotype research can guide combination therapy that will alter the tumor microenvironment, making tumor types than have been resistant to PD-1/L1 inhibitors sensitive to immunotherapy.
IDO Updates At ASCO: Incyte's Combos With Merck And Bristol Take Center Stage
The immuno-oncology highlight of the upcoming American Society of Clinical Oncology annual meeting will be clinical data for Incyte's epacadostat with Merck's Keytruda as well as data with Bristol's Opdivo.
Deal Watch: Merck, Incyte Double Down On Keytruda/Epacadostat Collaboration
Expansion of 2015 development partnership adds lung and bladder cancer as well as renal and head-and-neck carcinoma to trials of the two immuno-oncology drugs. Jazz licenses Japanese rights to two of its commercial products to Nippon Shinyaku.